Keyphrases
Tuberculosis
100%
Active Tuberculosis
100%
Food Supplements
100%
Clinical Trials
40%
Placebo
40%
Treg
40%
Immunogenicity
40%
Tuberculosis Incidence
40%
Tuberculin
40%
Mechanism of Action
20%
Murine Model
20%
Pediatric Population
20%
Adverse Effects
20%
Close Contact
20%
Am(III)
20%
Georgia
20%
Interleukin-10
20%
Interleukin-17 (IL-17)
20%
Risk Reduction
20%
Five-year-olds
20%
Telephone
20%
Spleen
20%
Between-group
20%
Lung
20%
Randomized Placebo-controlled Trial
20%
Incubation
20%
Placebo Groups
20%
Population Characteristics
20%
Splenocytes
20%
Sputum
20%
Medical Center
20%
HIV-positive
20%
Bacillary Load
20%
Neutrophil Infiltration
20%
Specific Memory
20%
Efficacy Study
20%
CD39
20%
Placebo-controlled Clinical Trial
20%
Chemoprophylaxis
20%
Galenic Preparations
20%
Heat-killed
20%
Mycobacterium Manresensis
20%
CD4+CD25+
20%
Dose Tolerance
20%
Purified Protein Derivative
20%
Tuberculin Purified Protein Derivative
20%
Mycobacterium Fortuitum Group
20%
Memory Regulatory T Cells
20%
Medicine and Dentistry
Tuberculosis
100%
Food Supplement
100%
Placebo
100%
Controlled Clinical Trial
40%
Mantoux Test
40%
Clinical Trial
40%
Immunogenicity
40%
Tuberculin
40%
Ex Vivo
20%
Human Immunodeficiency Virus
20%
Low Drug Dose
20%
Adverse Event
20%
Population and Population Related Phenomena
20%
Sputum
20%
Incubation
20%
Neutrophil Chemotaxis
20%
Chemoprophylaxis
20%
Mycobacterium fortuitum
20%
Regulatory T Cell
20%
Lung
20%
Volunteer
20%
Pediatrics
20%
Efficacy Study
20%
Interleukin 17
20%
Interleukin 10
20%
Mycobacteria
20%
Immunology and Microbiology
Regulatory T Cell
100%
Immunogenicity
66%
Tuberculin
66%
Mantoux Test
66%
Mycobacteria
33%
Splenocyte
33%
Low Drug Dose
33%
CD4
33%
CD25
33%
Human Immunodeficiency Virus
33%
Preclinical Study
33%
Interleukin 10
33%
Sputum
33%
New Species
33%
Population and Population Related Phenomena
33%
Neutrophil Chemotaxis
33%
Mycobacterium fortuitum
33%
C3HeB/Fe Mouse
33%
Interleukin 17
33%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Tuberculosis
100%
Tuberculin
80%
Controlled Clinical Trial
40%
Clinical Trial
40%
Immunogenicity
40%
HIV
20%
Preclinical Study
20%
C3HeB/Fe Mouse
20%
Efficacy Study
20%
Chemoprophylaxis
20%
Adverse Event
20%
Interleukin 17
20%
Mycobacteria
20%
Interleukin 10
20%
Mycobacterium fortuitum
20%